Clinical research observations with use of exubera in patients with type 1 and 2 diabetes

Diabetes Technology and Therapeutics

Volumn 9, Issue SUPPL. 1, 2007, Pages

  Cefalu, William T ^a   Wang, Zhong Q ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; HEMOGLOBIN A1C; INSULIN; METFORMIN; ROSIGLITAZONE; SULFONYLUREA;

CONFERENCE PAPER; DIABETES CONTROL; DIET THERAPY; DRUG DELIVERY SYSTEM; DRY POWDER; EXERCISE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; EQUIPMENT DESIGN; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN ANTIBODIES; NEBULIZERS AND VAPORIZERS; THIAZOLIDINEDIONES;

EID: 34250704756     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2007.0223     Document Type: Conference Paper

References (24)

1. Diabetes Control and Complications Trial Research Group: The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial. N Engl J Med 1993;329;978-986.
2. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-853.
3. Kahn SE: The importance of the beta-cell in the pathogenesis of type 2 diabetes mellitus. Am J Med 2000;108(Suppl 6a):2S-8S.
4. Weyer C, Bogardus C, Mott DM, Pratley RE: The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999;104:787-794.
5. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B: Management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2006;29:1963-1972.
6. Cefalu WT: Point: pulmonary inhalation of insulin: another "brick in the wall." Diabetes Care 2007;30: 439-441.
7. Cefalu WT: Evolving strategies for insulin delivery and therapy. Drugs 2004;64:1149-1161.
8. Rosenstock J, Zinman B, Murphy LJ, Clement SC, Moore P, Bowering CK, Hendler R, Lan SP, Cefalu WT: Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2005;143:549-558.
9. Skyler JS, Cefalu WT, Kourides IA, Landschulz WH, Balagtas CC, Cheng SL, Gelfand RA: Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet 2001;357: 331-335.
10. Quattrin T, Belanger A, Bohannon NJ, Schwartz SL; Exubera Phase III Study Group: Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004;27:2622-2627.
11. Skyler JS, Weinstock RS, Raskin P, Yale JF, Barrett E, Gerich JE, Gerstein HC; Inhaled Insulin Phase III Type 1 Diabetes Study Group: Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. Diabetes Care 2005;28:1630-1635.
12. Skyler JS, Jovanovic L, Klioze S, Reis J, Duggan W; Inhaled Human Insulin Type 1 Diabetes Study Group: Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes. Diabetes Care 2007;30:579-585.
13. DeFronzo RA, Bergenstal RM, Cefalu WT, Pullman J, Lerman S, Bode BW, Phillips LS; Exubera Phase III Study Group: Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial. Diabetes Care 2005;28:1922-1928.
14. Barnett AH, Dreyer M, Lange P, Serdarevic-Pehar M: An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with metformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea. Diabetes Care 2006;29:1282-1287.
15. Barnett AH, Dreyer M, Lange P, Serdarevic-Pehar M: An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on metformin. Diabetes Care 2006;29:1818-1825.
16. Hollander PA, Blonde L, Rowe R, Mehta AE, Milburn JL, Hershon KS, Chiasson JL, Levin SR: Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6 month, randomized, comparative trial. Diabetes Care 2004;27: 2356-2362.
17. DeFronzo RA: Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999;131:281-303.
18. Riddle M: Combining sulfonylureas and other oral agents. Am J Med 2000;108(Suppl 6a):15S-22S.
19. Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A: Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005;28:950-955.
20. Cefalu WT, Skyler JS, Kourides IA, Landschulz WH, Balagtas CC, Cheng S, Gelfand RA; Inhaled Insulin Study Group: Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med 2001;134:203-207.
21. Cefalu W, Rosenstock J, Klioze S, Foyt H, Ogawa M, St. Aubin L, Duggan W: Sustained efficacy and tolerability of inhaled human insulin (Exubera®). Therapy over 2 years: patients with type 2 diabetes [abstract PS 85]. In: Eropean Association for the Study of Diabetes 42nd Annual Meeting, European Association for the Study of Diabetes, Copenhagen, Denmark, and Malmoe, Sweden, 2006:1004.
22. Fineberg SE, Kawabata T, Finco-Kent D, Liu C, Krasner A: Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial. J Clin Endocrinol Metab 2005;90:3287-3294.
23. Cappelleri JC, Cefalu WT, Rosenstock J, Kourides IA, Gerber RA: Treatment satisfaction in type 2 diabetes: a comparison between an inhaled insulin regimen and a subcutaneous insulin regimen. Clin Ther 2002; 24:552-564.
24. Testa MA, Simonson DC: Satisfaction and quality of life with premeal inhaled versus injected insulin in adolescents and adults with Type 1 diabetes. Diabetes Care 2007 Mar 2; [Epub ahead of print].